china

3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.

Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.

The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer.

Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.

The trial that showed anlotinib helps patients with lung cancer live longer after other treatments have failed, the basis of one of China's most used cancer pills.

Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.

Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial.

Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.

Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.

Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.

Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.

Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898.

Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727.

Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.

Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.

Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008.

Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer.

The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result.

The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease.

Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.

The China Anti-Cancer Association is the country's largest cancer society, publishing the CACA guidelines that aim to reflect Chinese patients and Chinese drugs rather than imported recommendations.

CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.

Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.

Chongqing University Cancer Hospital is the main cancer centre for south-west China's largest city and a growing site for domestic trials.

CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.

CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China.

Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials.

The trial that made dalpiciclib the first Chinese CDK4/6 inhibitor approved, more than doubling the time before breast cancer grew when added to fulvestrant.

Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.

Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.

Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.

Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.

Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia.

Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment.

The single-arm trial that won eque-cel its approval in China, with almost every patient responding and most reaching deep remissions.

The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug.

Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.

Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation.

Ge Li founded WuXi AppTec in Shanghai in 2000 and built the contract research and manufacturing network that much of the world's cancer pipeline now depends on.

The trial behind sugemalimab's approval in China and later Europe, showing a PD-L1 antibody plus chemotherapy delays progression in both main types of lung cancer.

GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.

Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world.

Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.

The first phase 3 win for ivonescimab, in lung cancer that has stopped responding to EGFR pills, and the basis of its first approval in China.

Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib.

Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.

IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.

Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head.

ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.

Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023.

Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.

InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.

Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.

China's national blood disease hospital in Tianjin is where the CD19 binder behind the CAR-T inati-cel was made; it runs large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.

InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.

QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.

Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.

Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.

Jia Fan leads one of the world's busiest liver cancer surgery and transplant programmes and the proteogenomic studies that mapped how hepatitis B-related liver cancer differs at the molecular level.

Jiangsu Cancer Hospital in Nanjing is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials.